Dossier assessment

Ibrutinib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)

Status
Status: Commission completed
Project no.
G14-11
Last updated

Report documents

  1. Dossier assessment

    Ibrutinib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)

    published on
    Document type
    PDF document, 218 kB, DE, not accessible

Additional information

Federal Joint Committee (G-BA)

2015-04-16 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
G14-11
Commission
Commission awarded on 22.10.2014 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Health Economics
Topic
Cancer
Note

In accordance with § 35a (para. 1, sentence 10) Social Code Book V, the added medical benefit of orphan drugs is deemed as proven by the fact that they have been approved. For the Ibrutinib report commissioned by the Federal Joint Committee (G-BA), IQWiG therefore solely assesses the information on patient numbers and costs in the pharmaceutical company's dossier. After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. The resolution on the extent of added benefit is passed by the G-BA after the hearing. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Connected Projects

  1. Dossier assessment

    Ibrutinib (new therapeutic indication, Waldenström macroglobulinaemia) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A19-78
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Ibrutinib (new therapeutic indication, chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A19-77
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Ibrutinib (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A16-60
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Ibrutinib (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A16-39
    Last updated

    Status: Commission completed

  5. Dossier assessment

    Ibrutinib - Benefit assessment according to §35a Social Code Book V

    Project no.
    A16-04
    Last updated

    Status: Commission completed

  6. Dossier assessment

    Ibrutinib (new therapeutic indication) - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)

    Project no.
    G15-07
    Last updated

    Status: Withdrawn commission

  7. Dossier assessment

    Ibrutinib (chronic lymphocytic leukaemia, first line) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-04
    Last updated

    Status: Commission completed

  8. Dossier assessment

    Ibrutinib (CLL) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A20-88
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form